Neuropore and UCB unite in a new collaborative deal to combat Parkinson’s Disease

WASHINGTON - Jan. 19, 2015 - PRLog -- UCB has entered into a deal with Neuropore Therapies Inc to develop and commercialize therapeutics to slow the progression of Parkinson’s disease and related disorders. UCB will receive the world-wide exclusive license to develop and commercialize Neuropore’s NPT200-11, an investigational small molecule which targets pathogenic alpha-synuclein. NPT200-11 is currently in preclinical development and will enter Phase 1 clinical trials in 2015. Neuropore is expected to receive US$20 million as an upfront payment and could potentially receive US $460 million based on regulatory and sales-based milestones plus royalties on net sales. UCB will lead further clinical development, regulatory and commercialization activities.

“We are excited to partner with UCB, a global leader in developing drugs to treat neurological diseases,” said Dieter Meier, Neuropore’s CEO. “By working together we wish to accelerate the development of new treatments that can halt or slow the progression of Parkinson’s disease and other neurodegenerative diseases for patients who suffer from such debilitating conditions. UCB’s commitment and expertise in this field offers the best opportunity to collaboratively develop orally available small molecules to treat diseases that affect large patient populations and possibly certain orphan diseases. We anticipate that this partnership will contribute to Neuropore’s further growth to become a leader in discovering and developing innovative nervous system therapies.”

An estimated seven to ten million individuals suffer from Parkinson’s disease worldwide. It is the second most common neurodegenerative disorder after Alzheimer’s disease. The treatments currently on the market are aimed at managing early motor symptoms of the disease however, as the disease progresses they become less effective.  Ismail Kola, President UCB New MedicinesTM stated, “People living with Parkinson’s disease need better treatment options, especially as there is currently no approved treatment that addresses a fundamental pathological mechanism in Parkinson’s disease. With Neuropore’s NPT200-11, we have the opportunity to develop a disease modifying treatment option for patients with Parkinson’s disease and other synucleinopathies.”

ABOUT US

The NAPSRx® is a trade association for pharmaceutical sales reps, sales managers and sales trainers who work in the pharmaceutical industry. NAPSRx® provides Continuing Medical Education to its members as well as CNPR® Certification to candidates who look to enter a pharmaceutical sales career. The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.
Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/ (http://napsronline.org/)